JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $41.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by analysts at JPMorgan Chase & Co. from $39.00 to $41.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 199.05% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Citigroup decreased their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Finally, Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Trading Down 2.8 %

Shares of SNDX stock opened at $13.71 on Thursday. The firm’s fifty day moving average price is $14.24 and its two-hundred day moving average price is $16.11. Syndax Pharmaceuticals has a 1 year low of $12.06 and a 1 year high of $25.07. The firm has a market capitalization of $1.18 billion, a P/E ratio of -3.78 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, equities research analysts forecast that Syndax Pharmaceuticals will post -3.72 EPS for the current fiscal year.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock valued at $336,087 in the last ninety days. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Syndax Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Atria Investments Inc bought a new stake in Syndax Pharmaceuticals during the third quarter worth about $364,000. Quest Partners LLC raised its position in shares of Syndax Pharmaceuticals by 31.0% in the 3rd quarter. Quest Partners LLC now owns 17,858 shares of the company’s stock valued at $344,000 after buying an additional 4,223 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $15,165,000. Intech Investment Management LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $429,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Syndax Pharmaceuticals by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock valued at $13,397,000 after acquiring an additional 41,458 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).